[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500007":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":59,"collaborators":61,"id":65,"slug":25,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":22,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":25,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Generation Next Fertility","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"oPRP injections","EXPERIMENTAL","Patients own prepared PRP will be injected into each ovary",[13],"Other: oPRP",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Patient's serum will be injected into the ovary (not rich with platelets)",[19],"Other: Placebo- Serum",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"oPRP","Prepared sample from patient's own blood collected and processed. Either PRP or serum is injected into the patient's ovary. All other care is standard for the IVF process",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo- Serum","Patient's serum is injected into ovary instead of PRP as placebo",[15],[31],{"name":32,"affiliation":5,"role":33},"Jesse Hade, MD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Alicia Broussard, PhD","CONTACT","3174456958","a.broussard@generationnextfertility.com",{"name":32,"role":37,"phone":41,"phoneExt":25,"email":42},"2126410906","j.hade@generationnextfertility.com",[44],{"facility":5,"status":45,"city":46,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","New York","10022","United States",{"type":50,"coordinates":51},"Point",[52,53],-74.00597,40.71427,{"lat":53,"lon":52},[56,58],{"name":32,"role":37,"phone":57,"phoneExt":25,"email":42},"212-641-0906",{"name":36,"role":37,"phone":41,"phoneExt":25,"email":39},{"type":60,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[62],{"name":63,"class":64},"Igenomix","INDUSTRY","100500007",false,"NCT05790655","Ovarian PRP for Diminished Ovarian Reserve","Ovarian Platelet-Rich Plasma Injections for Diminished Ovarian Reserve Patients: A Double-Blinded Placebo-Control Trial","Inclusion Criteria:\n\n* Clinical diagnosis of diminished ovarian reserve\n* Clinical diagnosis of poor ovarian response\n* Women age 35-42\n\nExclusion Criteria:\n\n* Clinical diagnosis of premature ovarian failure\n* Clinical diagnosis of menopause.\n* Under 35 years of age\n* Over 42 years of age",true,"FEMALE","35 Years","42 Years",{"count":76,"type":77},230,"ESTIMATED","INTERVENTIONAL",[80],"NA","This prospective double-blinded randomized placebo control study aims to determine if In Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously have the lowest chance of pregnancy and live birth compared to age-matched peers with a normal or robust ovarian reserve.",[83],"Diminished Ovarian Reserve",[85,86,87,88,89,90,91],"Ovarian Platelet Rich Plasma","DOR","Ovarian PRP","IVF","PRP","PGT-A","ICSI","2025-02-11",{"date":94,"type":95},"2025-02-13","ACTUAL",{"date":97,"type":95},"2023-10-07",{"date":99,"type":77},"2025-12-31",{"name":5,"class":6},1]